SCIENCE

Publications & presentations

Gordon Research Conference on Induced Proximity Modalities and Therapeutics

June 24, 2026

Interdict’s CEO Larry Hamann presents today at the inaugural 2026 Gordon Research Conference on Induced Proximity Modalities and Therapeutics: "Context-Dependent Translation Inhibition to Address Historically Intractable Therapeutic Targets in Oncology and Neurodegeneration"

Context-dependent translation inhibition as a cancer therapeutic modality

February 24, 2026

Interdict announces the proof-of-concept study characterizing context-dependent human translation inhibitors, called Interdictors™, as a novel cancer therapeutic modality is now published and available as open access in Nature Communications.

View publication

Context-Dependent Translation Inhibition as a Novel Cancer Therapeutic Modality

January 9, 2025

Interdict releases proof-of-concept pre-print study demonstrating the ability to design, synthesize, and characterize context-dependent human translation inhibitors, called Interdictors™, as a novel cancer therapeutic modality.

View publication

Sequence-Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality

May 30, 2025

Interdict’s CEO Larry Hamann presents today at the Dana Farber Targeted Degradation Webinar Series an overview of our scientific platform and pipeline efforts.

View presentation